Rockville, Maryland 20850

  • HIV Seronegativity


The purpose of this study is to determine the best way to administer the candidate HIV vaccine, ALVAC HIV-1 (vCP205).

Study summary:

Healthy adult volunteers are assigned randomly to either a vaccine or placebo group. Injections are received either intramuscularly, intradermally, or by delivery under the skin of the volunteer's own white blood cells which have had dendritic cell reinfusion. Volunteers are vaccinated at 0, 1, 3, and 6 month time points. Volunteers are closely monitored for 1 hour after vaccination and keep a diary of symptoms for 1 week post-immunization. Volunteers undergo leukopheresis at the start of the study and after the last vaccination at Walter Reed Army Medical Center. Volunteers receive compensation benefits.


Inclusion Criteria Volunteers may be eligible for this study if they: - Are legal US residents. - Are healthy adults from 18 to 55 years of age. Exclusion Criteria Volunteers will not be eligible for this study if they: - Are HIV-positive. - Are at highest risk for HIV infection. - Are pregnant or breast-feeding. - Are allergic to eggs or neomycin. - Use certain prescription medications.



Primary Contact:

Principal Investigator
Mary Marovich

Backup Contact:


Location Contact:

Rockville, Maryland 20850
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.